Bausch Health announces FDA approval of Duobrii for plaque psoriasis
Bausch Health and its dermatology business, Ortho Dermatologics, announced that the U.S. Food and Drug Administration has approved the New Drug Application for Duobrii Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. "Duobrii is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation," the company said. Duobrii is expected to be available in June. Duobrii Lotion is priced at $825 for a supply of a 100-gram tube, which "is more than 50% lower than other branded topical combination products," according to Bausch. Additionally, through the company's access program, most eligible, commercially insured patients will have a co-pay between $25 and $40, the company said.